BioArctic (OM:BIOA B) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BIOA B Stoklara Genel Bakış

BioArctic AB (publ) İsveç'te merkezi sinir sistemi bozuklukları olan hastalar için biyolojik ilaçlar geliştirmektedir.

BIOA B temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	6/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 71.5% daha düşük bir oranda işlem görüyor

Kazançların yılda 98.4% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 85% oranında artacağı konusunda hemfikir

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

BioArctic AB (publ) Rakipler

Bonesupport Holding

OM:BONEX

SEK 21.1b

BioGaia

OM:BIOG B

SEK 11.1b

Vitrolife

OM:VITR

SEK 31.8b

Hansa Biopharma

OM:HNSA

SEK 2.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BioArctic
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 157.70
52 Haftanın En Yüksek Seviyesi	SEK 288.40
52 Haftanın En Düşük Seviyesi	SEK 142.90
Beta	-0.19
11 Aylık Değişim	-13.35%
3 Aylık Değişim	-28.06%
1 Yıllık Değişim	-43.68%
33 Yıllık Değişim	8.31%
5 Yıllık Değişim	136.08%
Halka arzdan bu yana değişim	443.79%

Son Haberler & Güncellemeler

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 15

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Aug 23

Hissedar Getirileri

	BIOA B	SE Biotechs	SE Pazar
7D	-1.5%	-4.5%	-1.5%
1Y	-43.7%	25.8%	23.4%

Getiri vs. Endüstri: BIOA B geçen yıl % 28.8 oranında getiri sağlayan Swedish Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BIOA B geçen yıl % 25.1 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BIOA B's price volatile compared to industry and market?
BIOA B volatility
BIOA B Average Weekly Movement	11.7%
Biotechs Industry Average Movement	9.2%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

İstikrarlı Hisse Senedi Fiyatı: BIOA B hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BIOA B 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala Swedish hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	96	Gunilla Osswald	www.bioarctic.se

BioArctic AB (publ) İsveç'te merkezi sinir sistemi bozuklukları olan hastalar için biyolojik ilaçlar geliştirmektedir. Şirket, Alzheimer hastalığının tedavisi için Lecanemab, Lecanemab AHEAD 3-45 ve Lecanemab Back-up'ı geliştirmektedir. Ayrıca şirket, antikorların beyne alımını teşvik etmek için kan-beyin bariyeri teknolojisi ve Brain Transporter ile birleştirilen Alzheimer hastalığına karşı AD-BT2802 ve AD-BT2803 ilaç projelerini geliştirmektedir.

BioArctic AB (publ) Temel Bilgiler Özeti

BioArctic'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BIOA B temel i̇stati̇sti̇kler
Piyasa değeri	SEK 13.94b
Kazançlar(TTM)	-SEK 88.28m
Gelir(TTM)	SEK 299.35m

46.6x

P/S Oranı

-157.9x

F/K Oranı

BIOA B aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BIOA B gelir tablosu (TTM)
Gelir	SEK 299.35m
Gelir Maliyeti	SEK 82.67m
Brüt Kâr	SEK 216.68m
Diğer Giderler	SEK 304.96m
Kazançlar	-SEK 88.28m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 14, 2024

Hisse başına kazanç (EPS)	-1.00
Brüt Marj	72.38%
Net Kâr Marjı	-29.49%
Borç/Özkaynak Oranı	0%

BIOA B uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BIOA B Stoklara Genel Bakış

Ödüller

Risk Analizi

BioArctic AB (publ) Rakipler

OM:BONEX

SEK 21.1b

OM:BIOG B

SEK 11.1b

OM:VITR

SEK 31.8b

OM:HNSA

SEK 2.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Recent updates

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Price target decreased by 8.6% to kr336

New major risk - Share price stability

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Consensus EPS estimates fall by 60%

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Consensus forecasts updated

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher